Back to news

Omeros Corporation Reports Third Quarter 2026 Financial Results

Business Wire•16/11/2026•16:02 ET
0

Key Highlights

  • ➤YARTEMLEA gross revenue reached $41.8 million, up 29.6% quarter over quarter
  • ➤Non-GAAP adjusted net income rose to $4.7 million from $1.8 million
  • ➤GAAP net loss was $57.4 million, including a $62.0 million non-cash loss
  • ➤2029 Notes repurchases reduced potential share issuance by approximately 4.9 million shares
  • ➤EMA’s CHMP issued a negative opinion on narsoplimab’s TA-TMA application

Expert Statements

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow. We are investing in field education to make earlier recognition of TA-TMA and timely treatment with YARTEMLEA part of everyday transplant care. We are also working to expand TA-TMA patient access through international regulatory approvals and named-patient programs. In the U.S., we are helping transplant centers understand YARTEMLEA’s reimbursement advantages, including additional Medicare inpatient payments under NTAP, effective October 1, and favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA beginning January 1, 2027. We see YARTEMLEA not simply as a TA-TMA drug, but as an endothelial injury drug with broad therapeutic potential. YARTEMLEA revenues are funding our efforts to expand its indications, with clinical studies expected to begin soon in ARDS and TA-TMA prevention, and to initiate the Phase 2 clinical program for our long-acting MASP-2 inhibitor OMS1029. Together with expected zaltenibart-related milestone payments from Novo, these revenues are driving the rest of our pipeline forward: the OMS527 Phase 2 trial in cocaine use disorder planned to start early next year; the OncotoX-AML Phase 1b trial slated for late 2027; T-CAT, now in IND-enabling studies; and oral MASP-2 and MASP-3 inhibitors advancing toward the clinic. Across these first-in-class programs, as with YARTEMLEA, our objective remains to improve outcomes and save patients’ lives.”

Omeros Corporation Reports Third Quarter 2026 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include:

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in